ArticleEcancermedicalscience2025
Association between tumour necrosis factor-a polymorphism and cervical cancer in Lagos State, Nigeria.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac).JCO global oncology · 2025Trial
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Comparison analysis of serum interleukin-6 levels and cervical cancer.Ecancermedicalscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: The data on tumour necrosis factor-α (TNF-α) promoter gene polymorphism in the African population are relatively limited, especially in Nigerian women. Objectives: This study aimed to determine the prevalence and allele distribution of three TNF-α promoter gene SNPs loci - rs361525 (-238 G>A), rs1799964(-1031 T>C) and rs1800629 (-308 G>A) in women with cervical cancer (CC) and then evaluated the association between TNF-α SNPs and CC among women in Lagos, Nigeria. Methods: This is a cross-sectional study of 75 unmatched human immunodeficiency virus (HIV)-infected and uninfected women with and without CC enrolled from October 2021 to January 2023 at the gynaecological oncology, cytology, adult HIV and blood donor clinics of the Lagos University Teaching Hospital. About 5 mL of peripheral blood was collected from each participant for total Deoxyribonucleic acid extraction, primer synthesis and genotyping. The probability of developing CC based on the given SNP genotype was expressed as an odds ratio (OR) with a 95% confidence interval. Allelic frequency deviations from Hardy-Weinberg equilibrium were calculated using chi-square, and the statistical significance level was considered as two-tailed and set at Results: Our study found that TNF-α -1031 T>C polymorphism was significantly associated with increased CC risk in HIV-negative women (HIV+/CC-; OR = 1.4, 95%CI 0.23-8.42, Conclusion: We observed that HIV-negative and HIV-positive women who carry the C allele of -1031T>C and the A allele of -308G>A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.